Suicidal Ideation (SI)

According to the World Health Organization, every year approximately 800,000 people worldwide take their own life and many more attempt suicide.1 The U.S. Centers for Disease Control views suicide as a major public health concern in the U.S. as rates of suicide have been increasing for both men and women and across all age groups.2 Suicide is the 10th leading cause of death in the U.S. and is one of just three leading causes that are on the rise.3 According to experts in the field of suicidal ideation (SI), characterized as suicidal thoughts and behavior, the number of Americans who die by suicide is, since 2010, higher than those who die in motor vehicle accidents. People of all genders, ages, and ethnicities can be at risk for suicide. Suicidal ideation is complex and there is no single cause. The National Institute of Mental Health attributes many different factors to someone making a suicide attempt, including, but not limited to, depression, other mental health disorders or substance abuse. Additionally, according to reports released by the U.S. Department of Veterans Affairs (VA), the U.S. Military Veteran population is at significantly higher risk for suicide than the general population.

 We are collaborating with Baylor College of Medicine (Baylor) and the VA on a small Phase 1b clinical trial of AV-101 in healthy volunteer U.S. Military Veterans from Operation Enduring Freedom, Operation Iraqi Freedom or Operation New Dawn (the Baylor Study). The Baylor Study is a randomized, double-blind, placebo-controlled crossover study designed as a target engagement study as the first-step in our plans to test potential anti-suicidal effects of AV-101 in U.S. Military Veterans who respond to ketamine-based therapy. Dr. Marijn Lijffijt of Baylor is the Principal Investigator of the Baylor Study. Government funding from the VA is being provided for substantially all study costs.

  1. World Health Organization,
  2. U.S. Centers for Disease Control,
  3. U.S. Centers for Disease Control,